Navigation Links
Latest research suggests moderate coffee consumption is not associated with increased CVD risk
Date:9/27/2013

Coffee is one of the most extensively researched components in the diet. New studies are regularly being added to the already large body of scientific research, which overall suggests that moderate habitual coffee consumption is not associated with detrimental effects on cardiovascular health

Among recent studies, a new review paper1 highlights that for most healthy people, moderate coffee consumption is unlikely to adversely affect cardiovascular health. Furthermore a new paper2 concluded that higher green tea and coffee consumption is inversely associated with risk of CVD and stroke in the general population.

Considerable research has also been devoted to investigating associations between coffee consumption and key risk factors for cardiovascular disease, such as hypertension (high blood pressure) and elevated cholesterol. Most evidence suggests that regular moderate consumption of caffeinated coffee has no long-term effect on blood pressure and does not increase the risk of hypertension.

A recent study suggests that moderate consumption of paper-filtered coffee may have an unfavourable effect on plasma cholesterol3. The wider body of evidence indicates that the impact of coffee on cholesterol is dependent on the brewing method. Unfiltered coffee raises serum cholesterol levels whereas this is not the case with filter coffee because the cholesterol-raising compounds in coffee are retained in the paper filter.

Throughout 2013 coffee and mortality has been a subject of several scientific research papers, which have produced conflicting results. One study4 found a 21% increase in mortality rate in those drinking more than 28 cups of coffee a week. However recent data from a meta-analysis and systematic review5 assessed 23 studies and concluded that coffee consumption is, in fact, inversely related to the risk of mortality.


'/>"/>

Contact: Emma Knott
ISIC_Kaizo@kaizo.co.uk
020-317-64706
Kaizo
Source:Eurekalert

Page: 1

Related biology news :

1. Crestor Delivers Latest LDL-C Targets in High-Risk Patients at Lower Doses than Other Statins
2. Latest Southern Ocean research shows continuing deep ocean change
3. Coral reef experts to present latest coral reef science during July symposium
4. American Society for Microbiologys newest journal earns a high impact factor in latest rankings
5. BGI reports the latest finding on NMNAT1 mutations linked to Leber congenital amaurosis
6. MedNet Solutions Announces Latest Enhancements To Its iMedNet EDC eClinical Solution
7. American Physiological Societys latest conference focuses on integrative biology of exercise
8. Integrative and comparative biologists to discuss latest research
9. DDW: The latest and most thought-provoking research in GI
10. The latest genomic studies of wheat sheds new light on crop adaptation and domestication
11. Conference to highlight latest in postharvest pest control
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... DUBLIN , July 28, 2014 ... the "Biometrics Market in Latin America 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Biometrics measure and analyze biological ... facial patterns, irises, eye retinas, voice patterns, and hand ... one or more stored templates. The main purpose of ...
(Date:7/28/2014)... became the first man to reach the South Pole ... an international team of scientists led by Joe McConnell ... air pollution from industrial activities arrived long before. , ... spaced locations around the Antarctic continent, including the South ... reconstruction to date of lead pollution over the Earth,s ...
(Date:7/27/2014)... DURHAM, N.C. -- Microorganisms like bacteria and fungi can ... by antibiotics or antifungal drugs. These permanent mutations were ... strains to evolve. Now a new study has shown ... targets -- known as epimutations -- to gain the ... the new mechanism was discovered in a fungus called ...
Breaking Biology News(10 mins):Biometrics Market in Latin America 2014-2018 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 3Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3
... of evolution is periodically marked by explosions in biodiversity, ... of shapes and sizes. With a new analysis of ... have discovered that these diversifications proceeded head-first. By ... around the time of two separate extinction events, scientists ...
... are fascinating plant organs they not only anchor the ... Roots live in darkness and direct the activities of the ... Charles Darwin posited in The Power of Movement of Plants ... Due to the difficulty of accessing root tissue in ...
... Mediterranean diet with large amounts of vegetables and fish gives ... studies to be published by the Sahlgrenska Academy at the ... shown that a Mediterranean diet, based on a high consumption ... products such as meat and milk, leads to better health., ...
Cached Biology News:'Head-first' diversity shown to drive vertebrate evolution 2'Head-first' diversity shown to drive vertebrate evolution 3New tool offers unprecedented access for root studies 2
(Date:7/28/2014)... 28, 2014  InterMune, Inc. (NASDAQ: ITMN ... quarter 2014 financial results at the close of the ... call and webcast will be hosted by InterMune at ... Interested investors and others may participate in the conference ... conference ID#21728775. A replay of the webcast and teleconference will ...
(Date:7/25/2014)... Albany, NY (PRWEB) July 26, 2014 ... Trials Review, H2, 2014" provides data on the ... This report provides elemental information and data relating ... Cerebral Stroke. , View full global Ischemic Stroke ... It includes an overview of the trial numbers ...
(Date:7/25/2014)... July 25, 2014 According to a ... Drugs Market - Global Industry Analysis, Size, Share, Growth, ... drugs market is estimated at USD 161,056.5 million in ... of 10.1% from 2014 to 2020, to reach an ... The biological drugs market is witnessing a significant growth ...
(Date:7/25/2014)... /PRNewswire-iReach/ -- Xybion Corporation, the leading provider of ... in highly regulated industries, announced today that the ... Group Conference, Xybion International Exchange, on October 21-23, ... at the Sheraton Society Hill Hotel.  ... This year,s conference theme is Compliance Fusion.  ...
Breaking Biology Technology:InterMune to Release Second Quarter Financial Results on August 6 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3
... leaders, experts and foreign ministry delegations set to be involved in ... ... Singapore (PRWEB) March 2, 2009 -- Asia-Pacific,s largest and most ... Asia 2009 (GSA 2009), will be held in Singapore from 17th ...
... LOUIS, Feb. 27 A copy of the Company,s December ... Exchange Commission, may be obtained without charge at our website ... Sigma-Aldrich Corporation, P. O. Box 14508, St. Louis, Missouri 63178. ... Life Science and High Technology ...
... CV Therapeutics, Inc. (Nasdaq: CVTX ) today ... time in response to Astellas Pharma Inc.,s announcement that ... unsolicited tender offer for all outstanding common shares of ... in cash. CV Therapeutics, board of directors, in ...
Cached Biology Technology:News Release: Homeland Security to Take Centre Stage with Global Security Asia 2009 2News Release: Homeland Security to Take Centre Stage with Global Security Asia 2009 3CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas' Tender Offer 2CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas' Tender Offer 3
Mouse monoclonal [5H9] to RAD52 ( Abpromise for all tested applications). entrezGeneID: 5893 SwissProtID: P43351...
Purified anti-LAT...
Cytosol/Particulate Rapid Separation Kit Research Focus: other Storage Temperature: -20C Shipping Temperature: 4C...
Purified anti-human CD182 (CXCR2)...
Biology Products: